Empacoza TRIO 10/5/1000 mg &25/5/1000 mg
Pharmaceutical
Product Details:
- Active: EMPACOZA TRIO tablets for oral administration are available in four strengths containing: •10 mg empagliflozin (micronized), 5 mg linagliptin (micronized) and 1,000 mg metformin HCl •25 mg empagliflozin (micronized), 5 mg linagliptin (micronized) and 1,000 mg metformin HCl
- Pack of 30 Tablet
- Form: Tablet
- Concentration: 10/5/1000 mg & 25/5/1000 mg
- Speciality: All Specialities, Endocrinology & Metabolic, Cardiovascular
Leaflet :
Description :
Composition:
| EMPACOZA TRIO tablets for oral use contain: empagliflozin, linagliptin, and metformin HCl.
Each extended release film-coated tablet of EMPACOZA TRIO consists of an extended-release metformin hydrochloride core tablet that is coated with the immediate-release drug substances: empagliflozin and linagliptin.
EMPACOZA TRIO tablets for oral administration are available in four strengths containing: · 10 mg empagliflozin (micronized), 5 mg linagliptin (micronized) and 1,000 mg metformin HCl · 25 mg empagliflozin (micronized), 5 mg linagliptin (micronized) and 1,000 mg metformin HCl
INDICATIONS AND USAGE:
EMPACOZA TRIOis a combination of empagliflozin, linagliptin, and metformin hydrochloride (HCl) indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease
HOW SUPPLIED/STORAGE AND HANDLING
EMPACOZA TRIO tablets are available as follows:
|
This material has been approved by the Egyptian Medicines Authority under No. HF0027OA2670/092024.
Expiration date: 05/09/2025
Contact Us
Our Location
36 Al Sheikh Mohammed Al Nadi St., Off Mostafa El Nahaas St. 6th District. Nasr City, Cairo, Egypt.
Call Us
Quick Links
Newsletter
Sehetak Hayatak App
Dozova App